EQUASHIELD, a well-known name in healthcare innovation, has launched CellSHIELD, a new single-use device designed to enhance the production of cell and gene therapies. Using years of experience in closed system transfer devices (CSTD), the company is applying its expertise in safety and containment to the next generation of biopharmaceutical development. CellSHIELD is a fully enclosed, sterile, and disposable solution that supports both safety and efficiency, making it perfect for an industry that demands high standards and scalable tools.
Health Technology Insights: PainTEQ Raises Majority Growth Recapitalization Led by Signet and Windham Capital Partners
This new product addresses several major challenges faced by biopharma companies and contract manufacturing organizations, especially as cell and gene therapies become more complex and common. CellSHIELD’s closed design ensures product integrity by maintaining sterility and preventing contamination during processing. It helps cut manufacturing costs, reduces the risk of errors, and makes operations more efficient. It also simplifies daily workflows, reducing training time and allowing teams to get up to speed quickly. These benefits make it an excellent choice for companies looking to scale up their capabilities without compromising on quality.
CellSHIELD is versatile and works well in different stages of therapy production. It is suitable for in-process testing, sampling during cell culture procedures, transferring sterile fluids between containers, and removing air bubbles to improve product consistency. These steps, though routine, require a high level of precision and are crucial to maintaining quality across every batch. CellSHIELD provides a reliable, easy-to-use solution for these tasks while supporting regulatory compliance.
One of its key strengths is how it supports patient safety by keeping the entire process sterile from start to finish. This directly affects the quality of the therapy product. The device is also built for simple and repeatable use, which reduces the risk of human error and improves performance in the manufacturing environment. Because it doesn’t require complex training, it allows staff to become productive quickly. By applying EQUASHIELD’s long-standing experience in CSTD systems, the company has created a product that brings familiar safety standards to a new and rapidly evolving field.
Health Technology Insights: XRP Healthcare Launches Africa’s First HIPAA-Grade Health App
A representative from a leading cell therapy manufacturing partner shared that their experience with CellSHIELD has been very positive. They noted that the device led to almost no volume loss during operations, with reductions below 0.1 percent. Once staff started using it, the improvements compared to previous systems were obvious, and switching to CellSHIELD was an easy choice. Matt Stuckert, General Manager at EQUASHIELD, emphasized that CellSHIELD represents a meaningful step forward for the sector. He stated that the company has always focused on solving real challenges in healthcare with practical solutions. According to him, CellSHIELD is helping manufacturers bring advanced treatments to market more safely and efficiently. Jason Dutcher, Director of Strategic Accounts at EQUASHIELD, explained that the release of CellSHIELD is more than just a product launch. He sees it as a continuation of the company’s mission to improve how medical treatments are developed and delivered. He pointed out that the device not only enhances safety but also enables the kind of scalability needed to meet growing demand in the cell and gene therapy space. CellSHIELD will be showcased at the upcoming Cell and Gene Meeting on the Mesa, which is taking place from October 6 to 8 in Phoenix, Arizona. Attendees will have the opportunity to learn more about the system and how it is helping to reshape the future of cell and gene therapy manufacturing.
Health Technology Insights: Breath Diagnostics Technology Predicts Pneumonia Through Exhaled Breath Analysis
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
